Sec­ond piv­otal study bodes well for VBI's hep B vac­cine

In­vestors of VBI Vac­cines were unim­pressed last year when the com­pa­ny’s hep B vac­cine fell short in com­par­i­son to GSK’s es­tab­lished En­ger­ix-B in a key late-stage study. On Thurs­day, the Cam­bridge, Mass­a­chu­setts-based com­pa­ny un­veiled da­ta from a sec­ond piv­otal tri­al that ap­pears to ame­lio­rate some of those con­cerns.

VBI’s vac­cine, Sci-B-Vac, has al­ready se­cured ap­proval in Is­rael and ten oth­er coun­tries. It is en­gi­neered to mim­ic all three sur­face anti­gens of the hep B virus to in­duce a po­tent im­mune re­sponse and is be­ing de­vel­oped to work at low­er dos­es than ex­ist­ing hep B vac­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER